CompletedPhase 2NCT06050967

A Second-generation AI Based Therapeutic Regimen in Patients With Gaucher Disease Treated With Enzyme Replacement Therapy.

Studying Gaucher disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Hadassah Medical Organization
Principal Investigator
Noa Hurvitz, MD
Faculty of Medicine, Hebrew University, Jerusalem, Israel.
Intervention
Enzyme replacement therapy for Gaucher disease in combination with altus care application(combination_product)
Enrollment
5 enrolled
Eligibility
18 years · All sexes
Timeline
2022 – 2023

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06050967 on ClinicalTrials.gov

Other trials for Gaucher disease

Additional recruiting or active studies for the same condition.

See all trials for Gaucher disease →

← Back to all trials